Advances in Molecular Pathology Advances Series

Advances in Molecular Pathology reviews the year's most important findings and updates within the field in order to provide molecular pathologists with the current clinical information they need to improve patient outcomes. A distinguished editorial board, led by Dr. Gregory Tsongalis, identifies key areas of major progress and controversy and invites preeminent specialists to contribute original articles devoted to these topics. These insightful overviews in molecular pathology inform and enhance clinical practice by bringing concepts to a clinical level and exploring their everyday impact on patient care.

• Provides in-depth, clinical reviews in molecular pathology, providing actionable insights for clinical practice.

• Presents the latest information in the field under the leadership of an experienced editorial team. Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews.

The Landscape of Clinical Whole Genome Sequencing and the Emergence of Rapid Genetic Diagnosis in Critical Care
Blastic Plasmacytoid Dendritic Cell Neoplasm: Advances in Molecular Markers and Treatments
Molecular Classification of Diffuse Large B Cell Lymphoma: Impact on Prognosis and Treatment
B-Lymphoblastic Leukemia/Lymphoma: Newly Defined Entities and Subtypes by Molecular Methods
Molecular Diagnostics for Invasive Fungal Infections: Barriers to Widespread Adoption and Opportunities for Improvement
Recently Updated Sexually Transmitted Infection Screening Guidelines and Impact on Molecular Diagnostics
Quantitative Viral Load Monitoring: How far are We from Commutable Results?
The Current State of Pharmacoeconomics and Reimbursement for Pharmacogenomics
Long-read Sequencing for Germline Pharmacogenomic Testing
Practical Approaches to Pharmacogenomics in Patients Using Vitamins/Supplements and Medical Marijuana
Computer-Based Simulation of DNA Short[1]Read Next-Generation Sequencing: A Review of Software from a Clinical Perspective
Minimal Residual Disease Testing in Solid Tumors,
Mutational Signatures in Solid Tumors
Multi-Cancer Early Detection: Blood-Based Screening, Multiomics, Machine Learning, and New Clinical Pathways
Rapid Whole Genome Sequencing in Critically Ill Newborns
Molecular Diagnosis of Emerging Pathogens: Policy and Practical Considerations for Laboratorians

Gregory J. Tsongalis, PhD, HCLD, CC, FNACB., is the Vice Chair for Research and the Director of the Laboratory for Clinical Genomics and Advanced Technology (CGAT) in the Department of Pathology and Laboratory Medicine at the Dartmouth-Hitchcock Medical Center and Norris Cotton Cancer Center (NCCC) in Lebanon, NH. He is a Professor of Pathology and Laboratory Medicine at the Audrey and Theodor Geisel School of Medicine at Dartmouth in Hanover, NH and a member of the NCCC Molecular Therapeutics Program and the gastrointestinal and breast cancer clinical oncology groups. In 2016 he became a member of Dartmouth College's Program in Experimental and Molecular Medicine (PEMM), and he has served on the advisory board of the Health Care Genetics Professional Science Master's Degree Program and Diagnostic Genetic Sciences Program at the University of Connecticut (Storrs, CT). His area of expertise is in the development and implementation of clinical molecular diagnostic technologies. His research interests are in the pathogenesis of human cancers, personalized medicine and disruptive technologies. He has authored/edited twelve textbooks in the field of molecular pathology, published more than 230 peer reviewed manuscripts, and has been an invited speaker at both national and international meetings. He has served on numerous committees of the American Association for Clinical Chemistry, the American Society for Investigative Pathology, the Federation for American Societies for Experimental Biology, and the Association for Molecular Pathology (where he is a past President). He is active in the Alliance for Clinical Trials in Oncology, the Association for Molecular Pathology, the American Association for Clinical Chemistry, the American Association of Bioanalysts, and the American Society for Investigative Pathology. He serves on the editorial boards of 8 journals including Clinical Chemistry, Experimental and Molecular Pathology, and the Journal of Molecular Diagnostics. In